Taiwan Bio-Manufacturing Corp (TBMC, 臺灣生物醫藥製造), a government-initiated biotech company, on Friday staged its first public event in Taipei, during which it outlined its business model as being similar to that of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and highlighted its strategic alliance with a US technology-focused biomanufacturing company.
The company, co-established by the Industrial Technology Research Institute (ITRI) and the Development Center for Biotechnology (DCB) last year, on Friday announced a strategic alliance with National Resilience Inc from the US, which it said would give it access to the latter’s expertise in biologics, vaccines, nucleic acids, cell therapy and gene therapy.
TBMC was started following the government’s realization during COVID-19 that Taiwan needed to have its own pharmaceutical manufacturing capabilities, Minister of National Development Kung Ming-hsin (龔明鑫) told a news conference in Taipei.
Photo courtesy of Taiwan Bio-Manufacturing Corp
“It is both a health issue and a national security issue,” he said.
The pandemic put Taiwan’s inability to mass produce mRNA vaccines under the spotlight, TBMC chairman and acting CEO Michel Chu (瞿志豪) said.
“Then-vice president Chen Chien-jen (陳建仁) and then-vice premier Shen Jong-chin (沈榮津) initiated a plan to start a company that specializes in the contract manufacturing of biologics, but can also manufacture vaccines during a pandemic,” Chu said in a video played at the news conference that introduced the company.
Chu also told the audience that the company plans to make the most of Taiwan’s advantages — abundant biotech talent and an outstanding smart manufacturing industry — to catapult the country into becoming a global market for contract development and manufacturing organizations (CDMOs).
CDMOs are companies that provide pharmaceutical companies with outsourcing options for drug development and manufacturing to lower risks and capital investment in advanced manufacturing processes.
TBMC is thus not only similar to TSMC in name, but also in its strategy of specializing in advanced contract manufacturing, Chu said.
The establishment of TBMC is based on the “successful experience” of TSMC, he added.
TBMC, like TSMC in 1986, was partly funded by the government, first employed talent from the ITRI — and also the DCB in the case of TBMC — and used foreign technologies and innovations “to secure the trust of future clients,” Chu said.
TSMC’s foreign partner back then was Royal Philips Electronics NV — which transferred some of its semiconductor patents to TSMC — while TBMC works with National Resilience.
“There are very few CDMOs in the world that out-license,” Chu said. “Many companies around the world would love for TSMC to authorize its advanced manufacturing technologies to them, but TSMC would definitely not be willing to do so.”
The reason TBMC was able to strike a deal with National Resilience was not just its special Taiwan connection — Resilience vice chairman Patrick Yang (楊育民) is Taiwanese American — but also because Taiwan has the exceptional automated and smart manufacturing capabilities that large-molecule drugs increasingly require, Chu said.
Large-molecule drugs, also known as biologics, are made from living organisms, while small-molecule drugs, which make up most of the pharmaceutical drugs on the market, are chemically synthesized.
Minister of Economic Affairs Wang Mei-hua (王美花) added that Taiwan has an edge when comes to talent, its medical system and protection of intellectual property, but “as the pharmaceutical industry is a field where big companies gain the most by remaining large, international collaboration is crucial for Taiwan’s biotech industry.”
CDMO shows great potential for biologics in Asia, Wang said, adding that TBMC has established a lab in the Taipei Bioinnovation Park and that it aims to have a Good Manufacturing Practices-grade factory in the Hsinchu Biomedical Science Park within two years.
“We’re hoping TBMC will become another ‘sacred mountain that protects the nation’ [as TSMC is referred to among Taiwanese] in the decades to come,” the minister said.
A proposed 100 percent tariff on chip imports announced by US President Donald Trump could shift more of Taiwan’s semiconductor production overseas, a Taiwan Institute of Economic Research (TIER) researcher said yesterday. Trump’s tariff policy will accelerate the global semiconductor industry’s pace to establish roots in the US, leading to higher supply chain costs and ultimately raising prices of consumer electronics and creating uncertainty for future market demand, Arisa Liu (劉佩真) at the institute’s Taiwan Industry Economics Database said in a telephone interview. Trump’s move signals his intention to "restore the glory of the US semiconductor industry," Liu noted, saying that
On Ireland’s blustery western seaboard, researchers are gleefully flying giant kites — not for fun, but in the hope of generating renewable electricity and sparking a “revolution” in wind energy. “We use a kite to capture the wind and a generator at the bottom of it that captures the power,” said Padraic Doherty of Kitepower, the Dutch firm behind the venture. At its test site in operation since September 2023 near the small town of Bangor Erris, the team transports the vast 60-square-meter kite from a hangar across the lunar-like bogland to a generator. The kite is then attached by a
Foxconn Technology Co (鴻準精密), a metal casing supplier owned by Hon Hai Precision Industry Co (鴻海精密), yesterday announced plans to invest US$1 billion in the US over the next decade as part of its business transformation strategy. The Apple Inc supplier said in a statement that its board approved the investment on Thursday, as part of a transformation strategy focused on precision mold development, smart manufacturing, robotics and advanced automation. The strategy would have a strong emphasis on artificial intelligence (AI), the company added. The company said it aims to build a flexible, intelligent production ecosystem to boost competitiveness and sustainability. Foxconn
Leading Taiwanese bicycle brands Giant Manufacturing Co (巨大機械) and Merida Industry Co (美利達工業) on Sunday said that they have adopted measures to mitigate the impact of the tariff policies of US President Donald Trump’s administration. The US announced at the beginning of this month that it would impose a 20 percent tariff on imported goods made in Taiwan, effective on Thursday last week. The tariff would be added to other pre-existing most-favored-nation duties and industry-specific trade remedy levy, which would bring the overall tariff on Taiwan-made bicycles to between 25.5 percent and 31 percent. However, Giant did not seem too perturbed by the
RSS